Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of Syneron Medical (NASDAQ:ELOS), a global developer and marketer of aesthetic medical products, jumped as much as 12% after the company reported market-topping third-quarter earnings results.

So what: For the quarter, Syneron delivered a revenue increase of 4% to $62.7 million, helped most by its emerging business units segment that, though much smaller than its professional aesthetic device segment, delivered 17% year-over-year growth. Although Syneron's gross margin actually dipped 220 basis points to 53.1% from the year-ago period it still managed to expand its EPS to $0.04 from $0.03. By comparison, Wall Street was anticipating just a breakeven quarter in terms of EPS on $61.7 million in revenue.

Now what: With the exception of gyms and nutrition plan providers, let this earnings report serve as a reminder that you should never underestimate the drive of consumers to want to improve themselves aesthetically. Syneron's quarterly results also highlighted a pipeline update that looks filled with potentially new revenue growth drivers. Syneron certainly isn't cheap here at 22 times forward earnings, and it does have a fairly erratic history when it comes to earnings reports in terms of beats and misses, but I'd say it's definitely worth an add to your watchlist moving forward.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.